Insider Trading Alert - NHC, CENT And ALQA Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 28, 2015, 91 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $529.45 to $86,394,898.20.

Highlighted Stocks Traded by Insiders:

National Healthcare (NHC) - FREE Research Report

Abernathy James Paul, who is Director at National Healthcare, sold 1,310 shares at $63.00 on May 28, 2015. Following this transaction, the Director owned 19,937 shares meaning that the stake was reduced by 6.17% with the 1,310-share transaction.

The shares most recently traded at $63.80, up $0.80, or 1.25% since the insider transaction. Historical insider transactions for National Healthcare go as follows:

  • 4-Week # shares sold: 4,000
  • 12-Week # shares sold: 4,000
  • 24-Week # shares sold: 4,000

The average volume for National Healthcare has been 13,300 shares per day over the past 30 days. National Healthcare has a market cap of $895.5 million and is part of the health care sector and health services industry. Shares are up 0.22% year-to-date as of the close of trading on Thursday.

National HealthCare Corporation operates, manages, or provides services to skilled nursing facilities and associated assisted living centers, retirement centers, and home health care programs. The stock currently has a dividend yield of 2.54%. The company has a P/E ratio of 20.1. Currently, there are no analysts who rate National Healthcare a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NHC - FREE

TheStreet Quant Ratings rates National Healthcare as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and increase in net income. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full National Healthcare Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Central Garden & Pet (CENT) - FREE Research Report

Reed Michael A, who is Executive Vice President at Central Garden & Pet, sold 10,000 shares at $10.02 on May 28, 2015. Following this transaction, the Executive Vice President owned 136,051 shares meaning that the stake was reduced by 6.85% with the 10,000-share transaction.

The shares most recently traded at $9.73, down $0.29, or 3.01% since the insider transaction. Historical insider transactions for Central Garden & Pet go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 1,995
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 1,995
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 1,995

The average volume for Central Garden & Pet has been 38,100 shares per day over the past 30 days. Central Garden & Pet has a market cap of $117.9 million and is part of the consumer goods sector and food & beverage industry. Shares are up 12.76% year-to-date as of the close of trading on Thursday.

Central Garden & Pet Company produces and sells various products for the pet, and lawn and garden supplies markets in the United States. The company operates in two segments, Pet, and Lawn and Garden. The company has a P/E ratio of 27.5. Currently, there are no analysts who rate Central Garden & Pet a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CENT - FREE

TheStreet Quant Ratings rates Central Garden & Pet as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and notable return on equity. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full Central Garden & Pet Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Alliqua BioMedical (ALQA) - FREE Research Report

Johnson David Ian, who is President and CEO at Alliqua BioMedical, bought 10,000 shares at $4.65 on May 28, 2015. Following this transaction, the President and CEO owned 595,144 shares meaning that the stake was boosted by 1.71% with the 10,000-share transaction.

The shares most recently traded at $4.85, up $0.20, or 4.21% since the insider transaction. Historical insider transactions for Alliqua BioMedical go as follows:

  • 4-Week # shares bought: 661,840
  • 12-Week # shares bought: 661,840
  • 24-Week # shares bought: 661,840

The average volume for Alliqua BioMedical has been 91,000 shares per day over the past 30 days. Alliqua BioMedical has a market cap of $114.4 million and is part of the health care sector and drugs industry. Shares are down 11.51% year-to-date as of the close of trading on Thursday.

Alliqua BioMedical, Inc. provides wound care solutions. Currently, there are 4 analysts who rate Alliqua BioMedical a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALQA - FREE

TheStreet Quant Ratings rates Alliqua BioMedical as a sell. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full Alliqua BioMedical Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Alphabet, Caterpillar, Coca-Cola and Amazon - 5 Things You Must Know

Alphabet, Caterpillar, Coca-Cola and Amazon - 5 Things You Must Know

Apple Suppliers Slide After European, Asian Chipmakers Echo Smartphone Concerns

Apple Suppliers Slide After European, Asian Chipmakers Echo Smartphone Concerns

Global Stocks Edge Higher, But Bond Yields, Oil Prices May Test Market Strength

Global Stocks Edge Higher, But Bond Yields, Oil Prices May Test Market Strength

SAP Shares Leap After Cloud Business Prompts Full-Year Guidance Upgrade

SAP Shares Leap After Cloud Business Prompts Full-Year Guidance Upgrade

Sohn Conference Briefly Distracts From Barrage of Earnings -- ICYMI

Sohn Conference Briefly Distracts From Barrage of Earnings -- ICYMI